Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis

Gut

Volumn 54, Issue 7, 2005, Pages 987-993

  Albano, E ^a   Mottaran, E ^a   Vidali, M ^a   Reale, E ^a   Saksena, S ^b   Occhino, G ^a   Burt, A D ^b   Day, C P ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ARACHIDONIC ACID; ARACHIDONIC ACID HYDROPEROXIDE; CARDIOLIPIN; CHOLESTEROL; FERRITIN; IMMUNOGLOBULIN G; MALONALDEHYDE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPID PEROXIDATION; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SERUM ALBUMIN;

EID: 21044437187     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.057968     Document Type: Article

References (49)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:900-7.
2. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterol 2003;124:71-9.
3. Marchesini G, Bugianesi E, Forlani G, et al. Non alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatol 2003;37:917-23.
4. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterol 2001;120:1183-92.
5. Day CP. Pathogenesis of steatohepatitis. Best Practice Res Clin Gastroenterol 2002;16:663-78.
6. Wanless, IR, Lentz, JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatol 1990;12:1106-10.
7. Dixon JB, Bhathal PS, O'Brian PE. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterol 2001;121:91-100.
8. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatol 1999;29:664-70.
9. Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology 1998;114:842-5.
10. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-09.
11. Zamara E, Novo E, Marra F, et al. 4-hydroxynonenenal as a selective profibrogeneic stimulus for activated human hepatic stellate cells. J Hepatol 2004;40:60-8.
12. Yang SQ, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259-68.
13. 2 generation in liver mitochondria. Carcinogen 2000;21:983-9.
14. Laurent A, Nicco C, Tran Van Nhieu J, et al. Pivotal role of superoxide anron and benefical effect of antioxidant molecules in murine steatohepatitis. Hepatol 2004;39:1277-35.
15. Lequercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000;105:1067-75.
16. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-8.
17. Ip E, Farrell GC, Robertson G, et al. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-32.
18. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 2002;37:56-62.
19. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-1502.
20. Loguercio C, De Simone T, D'Auria MV, et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004;36:398-405.
21. Garcia-Monzon C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of non-alcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-24.
22. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38:414-18.
23. Lavine JE. Vitamin E treatment of non-alcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.
24. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-90.
25. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16.
26. Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-51.
27. Albano E, Clot P, Morimoto M, et al. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology 1996;23:155-63.
28. Rolla R, Vay D, Mottaran E, et al. Anti-phospholipid antibodies associated with alcoholic liver disease specifically recognize oxidized phospholipids. Gut 2001;49:852-9.
29. Mottaran E, Stewart SF, Rolla R, et al. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002;32:38-48.
30. Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003;38:42-9.
31. Stewart SF, Vidali M, Day CP, et al. Oxidative stress as a trigger for cellular immune response in patients with alcoholic liver disease. Hepatology 2004;39:197-203.
32. Grove J, Daly AK, Brown AStJM, et al. The Rsa I polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998;8:335-42.
33. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabet Care 1996;19:1138-41.
34. Brunt EM, Jannery CJ, Di Bisceglie AM, et al. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-76.
35. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
36. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
37. Yamada S, Kumazawa S, Ishii T, et al. Immunological detection of lipofuscin-like fluorophore derived from malondialdehyde and lysine. J Lipid Res 2001;42:1187-96.
38. Tuma DJ, Thiele GM, Xu D, et al. Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology 1996;23:872-80.
39. Xu D, Thiele GM, Beckenhauer JL, et al. Detection of circulating antibodies to malondialdehyde-acetaldehyde adducts in ethanol-fed rats. Gastroenterol 1998;115:686-92.
40. Rolla R, Vay D, Mottaran E, et al. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcoholic liver disease. Hepatology 2000;31:878-84.
41. Chikako N, Zhang SP, Raynor VJ, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004;40:781-6.
42. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001;35:297-306.
43. Schneiderhan W, Schmid-Kotsas A, Zhao J, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 2001;34:729-37.
44. Viñas O, Bataller R, Sancho-Bru P, et al. Human hepatic stellate cells show features of antigen presenting cells and stimulate lymphocyte proliferation. Hepatology 2003;38:919-29.
45. Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002;32:110-14.
46. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004;127:870-82.
47. Bellomo G, Maggi E, Poli M, et al. Autoantibodies against oxidatively modified low density in NIDDM. Diabetes 1995;44:60-6.
48. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 2000;47:475-88
49. (rrratum in Cardiovasc Res, 2003;57:869).